tbuckley/cabot-search huggingface dataset:
The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes
Authors: Yoon Jeong Choi, Haomiao Jia, Tal Gross, Katie Weinger, Patricia W. Stone, Arlene M. Smaldone
Journal: Diabetes Care (2016)

The purpose of this study was to evaluate the impact of Medicare Part D on reducing the financial burden of prescription drugs in older adults with diabetes.Using Medical Expenditure Panel Survey data (2000-2011), interrupted time series and difference-in-difference analyses were used to examine out-of-pocket costs for prescription drugs in 4,664 Medicare beneficiaries (≥65 years of age) compared with 2,938 younger, non-Medicare adults (50-60 years) with diabetes and to estimate the causal effects of Medicare Part D.Part D enrollment of Medicare beneficiaries with diabetes gradually increased from 45.7% (2006) to 52.4% (2011). Compared with years 2000-2005, out-of-pocket pharmacy costs decreased by 13.5% (SE 2.1) for all Medicare beneficiaries with diabetes following Part D implementation; on average, Part D beneficiaries had 5.3% (0.8) lower costs compared with those without Part D. Compared with a younger group with diabetes, out-of-pocket pharmacy costs decreased by 19.4% (1.7) for Medicare beneficiaries after Part D. Part D beneficiaries with diabetes who experienced the coverage gap decreased from 60.1% (2006) to 40.9% (2011) over this period.These findings demonstrate that although Medicare Part D has been effective in reducing the out-of-pocket cost burden of prescription drugs, approximately two out of five Part D beneficiaries with diabetes experienced the coverage gap in 2011. Future research is needed to examine the impact of Affordable Care Act provisions to close the coverage gap on the cost burden of prescription drugs for Medicare beneficiaries with diabetes.
p53 −/− synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia
Authors: Jingfang Zhang, Guangyao Kong, Adhithi Rajagopalan, Li Lu, Jingming Song, Mohamed Hussaini, Xinmin Zhang, Erik A. Ranheim, Yangang Liu, Jinyong Wang, Xin Gao, Yuan-I Chang, Kirby D. Johnson, Yun Zhou, David Yang, Bhavana Bhatnagar, David M. Lucas, Emery H. Bresnick, Xuehua Zhong, Eric Padron, Jing Zhang
Journal: Blood (2016)
HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.
Authors: Hartmut Goldschmidt, Pieter Sonneveld, Iris Breitkreuz, Bronno van der Holt, Axel Benner, Renee M.Y. Barge, Hans Salwender, Gerard M.J. Bos, Axel Glasmacher, Reinier Raymakers, Christof Scheid, Peter C. Huijgens, Ralph Naumann, Marinus H.J. van Oers, Annette Hänel, Edo Vellenga, Hans Martin, Pierre W. Wijermans, Anthony D. Ho, Petra H.M. Westveer, Gregor E.G. Verhoef, Uta Mazitschek, Henk M. Lokhorst
Journal: Blood (2005)
Can we identify patients with cancer at high risk for cachexia? A prospective study in pancreatic cancer (PC).
Authors: David R. Fogelman, Xin Shelley Wang, Manal Hassan, Donghui Li, Milind M. Javle, Matthew H.G. Katz, Michael J. Overman, Gauri R. Varadhachary, Rachna T. Shroff, Robert A. Wolff, James L. Abbruzzese
Journal: Journal of Clinical Oncology (2012)

219 Background: Identifying PC patients at high risk for cachexia may allow for early intervention to prevent it. Symptoms such as pain, nausea and anorexia may predict weight loss. Inflammatory cytokines are also associated with cachexia. We evaluated the ability of each to predict weight loss in newly diagnosed PC patients. Methods: Using the M. D. Anderson Symptom Inventory (MDASI), we assessed baseline symptoms in untreated advanced or metastatic PC patients. The survey assesses severity of symptoms on a 0-10 scale. Baseline serum levels of IL-1a, IL-1b, IGF-1, CXCL-12, CXCL-16, CRP, IL-6, IL-8, VEGF, CEA, and CA 19-9 were measured via ELISA. Using STATA (version 12), we generated multivariable logistic regression models with a backward selection procedure. This allowed us to evaluate all potential univariate correlates with 5% and 10% weight loss at P&lt;.1 to create a multivariate model containing variables of p&lt;.05. Student t-test was used to compare the mean values of cytokines across different strata. Results: We evaluated 72 patients (33M/39F). Weight loss of &gt;5% or death was observed in 44 patients (62%) and &gt;10% or death in 24 (34%). 61 pts (30M/31F) survived sixty days after the start of treatment with 5% and 10% weight loss seen in 33 (54%) and 13 (21%), respectively. Baseline severe loss of appetite was most strongly associated with weight loss (OR 15.3, p=.005), compared to those with a moderate loss of appetite (OR 4.7, p=.058), nausea (OR 9.4, p=.048), or shortness of breath (OR 7.4, p=.063). Neither diarrhea nor vomiting correlated with weight loss, nor did age, tumor markers, or treatment with platinum drugs, opiates, or erlotinib. Baseline cytokine levels were available for 23 patients. Mean CXCL-16 (p=.05) and IL-6 (p=.045) levels were greater in patients with weight loss. Serum erythropoietin levels may be negatively associated with weight loss (p=0.06). An analysis of the remaining patients’ samples will be available at the meeting. Conclusions: Both alterations in serum cytokines and specific symptoms may predict the development of cachexia. A more robust analysis of circulating cytokines may allow us to design interventions which prevent or delay cachexia in patients with advanced pancreatic cancer.
The Combination of Cyclophosphamide and Thalidomide During Induction Therapy for Multiple Myeloma Results in a High Rate of Stem Cell Mobilization Failure.
Authors: Holger W Auner, Luca Mazzarella, Lucy Cook, Richard Szydlo, Francesca Saltarelli, Jiri Pavlu, Jane F Apperley, Amin Rahemtulla
Journal: Blood (2009)
Troubled families, troubled policy making
Authors: Chris Bonell, Martin McKee, Adam Fletcher
Journal: BMJ (2016)

Families were let down by government’s ignorance of evidence based policy making

Last month, an independent evaluation of the first four years of the coalition government’s flagship Troubled Families Programme reported no discernible benefits for participating families, a failure that was both predictable and predicted.1 2 Sadly, it represents a massive and expensive waste of effort but at least provides a new case study to add to the extensive list of examples of how not to make policy.3 We note four lessons, each showing how ideas now commonplace in healthcare and public health might, had they been applied, have mitigated this monumental failure.

The first lesson is not to make policy as a rapid and ill considered response to high profile events. The Troubled Families Programme was conceived by the then prime minister in reaction to the 2011 riots across UK cities.4 The programme was not clearly formulated, and there was no logic model (a framework commonly used …
Persistent Improvement In Clinical Outcomes With Bortezomib-Thalidomide-Dexamethasone Vs Thalidomide-Dexamethasone Incorporated Into Double Autologous Transplantation For Multiple Myeloma: An Updated Analysis Of Phase 3 Gimema-MMY-3006 Study
Authors: Michele Cavo, Monica Galli, Annalisa Pezzi, Francesco Di Raimondo, Claudia Crippa, Massimo Offidani, Paola Tacchetti, Vittorio Montefusco, Franco Narni, Antonio Spadano, Norbert Pescosta, Elena Zamagni, Barbara Gamberi, Tommaso Caravita, Antonietta Pia Falcone, Chiara Nozzoli, Renato Zambello, Anna Furlan, Annamaria Brioli, Mario Boccadoro
Journal: Blood (2013)
Successful Treatment of a Patient with Glioblastoma and a Germline <i>POLE</i> Mutation: Where Next?
Authors: Alexandra Snyder, Jedd D. Wolchok
Journal: Cancer Discovery (2016)

Abstract Summary: Hypermutation and elevated neoantigen count in glioblastoma occurred in a patient harboring a germline POLE mutation and are associated with a clinical and antitumor immune response to PD-1 blockade. Cancer Discov; 6(11); 1210–11. ©2016 AACR. See related article by Johanns et al., p. 1230.
Protein Profiling of Hematopoietic Progenitor Cells and Leukemia Cells Identifies Novel Biomarkers Associated with Exposure of Polycyclic Aromatic Hydrocarbons
Authors: Hwan-Young Kim, Hye-Ran Kim, Stephanie J. Won, Hee-Jo Baek, Jae-Dong Moon, Jong-Hee Shin, Soon-Pal Suh, Hoon Kook, Dong-Wook Ryang, Myung-Geun Shin
Journal: Blood (2012)
PedsQL™ and EuroQol Most Responsive Measures To Change in Health-Related Quality of Life in Children with Hodgkin’s Disease.
Authors: Robert J. Klaassen, Nicholas J. Barrowman, Ronald D. Barr, Murray Krahn, Joanna Hughes, Paul Rogers, Ronald Anderson, Paul Grundy, S. Kaiser Ali, Rochelle Yanofsky, Lawrence Jardin, Oussama Abla, Mariana Silva, Anne-Sophie Carret, Dorothy Barnard, Mario Cappelli
Journal: Blood (2005)
Mutually Exclusive Cdk4-Cyclin D1 and Cdk6-Cyclin D2 Pairing Inactivates Rb and Promotes Cell Cycle Dysregulation in Multiple Myeloma.
Authors: Scott Ely, Maurizio Di Liberto, Ruben Niesvizky, Eunice Hatada, Hearn Cho, Daniel M. Knowles, Joseph Lane, Selina Chen-Kiang
Journal: Blood (2005)
A Role for Regulatory Cells in Tolerance Induction in Recipients of Haploidentical Combined Non-Myeloablative Bone Marrow and Kidney Transplantation?.
Authors: Giovanna Andreola, Meredith Chittenden, Juanita Shaffer, A. Benedict Cosimi, Tatsuo Kawai, Pete Cotter, Bimalangshu R. Dey, Nina Tolkoff-Rubin, Frederic Preffer, Susan Saidman, Kristin Kattleman, Thomas R. Spitzer, David H. Sachs, Megan Sykes
Journal: Blood (2007)
The transcription factor NR4A3 controls CD103+ dendritic cell migration
Authors: Kiwon Park, Zbigniew Mikulski, Goo-Young Seo, Aleksander Y. Andreyev, Paola Marcovecchio, Amy Blatchley, Mitchell Kronenberg, Catherine C. Hedrick
Journal: Journal of Clinical Investigation (2016)

The transcription factor NR4A3 (also known as NOR-1) is a member of the Nr4a family of nuclear receptors and is expressed in myeloid and lymphoid cells. Here, we have shown that Nr4a3 is essential for the migration of CD103+ dendritic cells (DCs) to lymph nodes (LNs). Nr4a3-deficient mice had very few CD103+ migratory DCs (mDCs) present in LNs, and mixed-chimera studies revealed that this migratory defect was cell intrinsic. We further found that CD103+ DCs from Nr4a3-deficient mice displayed a marked loss of surface expression of the chemokine CCR7. This defect in CCR7 expression was confined to CD103+ DCs, as CCR7 expression on T lymphocytes was unaffected. Moreover, CCR7 was not induced on CD103+ DCs from Nr4a3-deficient mice in response to either administration of the TLR7 agonist R848 or infection with Citrobacter rodentium in vivo. The transcription factor FOXO1 has been shown to regulate CCR7 expression. We found that FOXO1 protein was reduced in Nr4a3-deficient DCs through an AKT-dependent mechanism. Further, we found a requirement for NR4A3 in the maintenance of homeostatic mitochondrial function in CD103+ DCs, although this is likely independent of the NR4A3/FOXO1/CCR7 axis in the regulation of DC migration. Thus, NR4A3 plays an important role in the regulation of CD103+ mDCs by regulating CCR7-dependent cell migration.
Activity of Oral Panobinostat (LBH589) in Patients with Myelofibrosis.
Authors: Daniel J. DeAngelo, Andrew Spencer, Thomas Fischer, Thomas Kindler, Oliver G. Ottmann, Miles Prince, Frank J. Giles, Jorge Cortes, Angela Liu, Kathryn Parker, Ying Yan, Jeffrey W. Scott, Kapil N. Bhalla
Journal: Blood (2009)
Arterio‐venous fistula for automated red blood cells exchange in patients with sickle cell disease: Complications and outcomes
Authors: Marianne Delville, Sandra Manceau, Nassim Ait Abdallah, Jan Stolba, Sameh Awad, Thibaud Damy, Barnabas Gellen, Laurent Sabbah, Karima Debbache, Vincent Audard, Jean‐Louis Beaumont, Cécile Arnaud, Christelle Chantalat‐Auger, Françoise Driss, François Lefrère, Marina Cavazzana, Gilbert Franco, Frederic Galacteros, Jean‐Antoine Ribeil, Justine Gellen‐Dautremer
Journal: American Journal of Hematology (2016)

Erythrocytapheresis (ER) can improve outcome in patients with sickle cell disease (SCD). A good vascular access is required but frequently it can be difficult to obtain for sickle cell patients. Arterio-venous fistulas (AVFs) have been suggested for ER in SCD supported by limited evidence. We report the largest cohort of ER performed with AVFs from three French SCD reference centers. Data of SCD patients undergoing ER with AVFs in the French SCD reference center were retrospectively collected. The inclusion criteria were: SS or Sβ-Thalassemia and AVF surgery for ER. SCD-related complications, transfusion history, details about AVF surgical procedure, echocardiographic data before and after AVF, AVF-related surgical and hemodynamical complications were collected. Twenty-six patients (mean age 20.5 years, mean follow-up 68 months [11-279]) were included. Twenty-three patients (88.5%) required central vascular access before AVF. Fifteen AVFs (58%) were created on the forearm and 11 (42%) on the arm. Nineteen patients (73%) had stenotic, thrombotic or infectious AVF complications. A total of 0.36 stenosis per 1,000 AVF days, 0.37 thrombosis per 1,000 AVF days and 0.078 infections per 1.000 AVF days were observed. The mean AVF lifespan was 51 months [13-218]. One patient with severe pulmonary hypertension worsened after AVF creation and died. We report the first series of SCD patients with AVF for ER, demonstrating that AVFs could be considered as a potential vascular access for ER. Patients with increased risk for hemodynamic intolerance of AVFs must be carefully identified, so that alternative vascular accesses can be considered. Am. J. Hematol. 92:136-140, 2017. © 2016 Wiley Periodicals, Inc.
Defibrotide for Prophylaxis of Hepatic Veno-Occlusive Disease in Pediatric Hematopoietic Stem Cell Transplantation: Subanalysis Data from an Open-Label, Phase III, Randomized Trial
Authors: Selim Corbacioglu, Ansgar S. Schulz, Petr Sedlacek, Bernd Gruhn, Simone Cesaro, Peter Bader
Journal: Blood (2015)
CXCL9 Contributes To Chemotherapy-Induced Acute Intestinal Damage Through Proliferative Inhibition Of Epithelial Cells
Authors: Huili Lu, Hongyu Liu, Jiaqing Shen, Shunyan Weng, Lan Qian, Mingyuan Wu, Shunying Zhu, Yan Yu, Wei Han, Jianwei Zhu, Anja Moldenhauer
Journal: Blood (2013)
Abstract 18908: Incremental Value of Inefficient Deformation Indices for Predicting Response to Cardiac Resynchronization Therapy
Authors: Yi-Hsin Chan, Chun-Li Wang, Chi-Tai Kuo
Journal: Circulation (2012)

Background: Previous studies have identified 4 clinical characteristics associated with a favorable response to cardiac resynchronization therapy (CRT): female, left bundle-branch block (LBBB), QRS duration ≥ 150 ms and non-ischemic etiology. This study evaluated the incremental value of baseline inefficient-deformation and time-delay indices over clinical characteristics for predicting CRT response. Methods: Speckle-tracking longitudinal strain was analyzed in 119 CRT candidates. Patients were divided into subgroups according to sex (male vs female), QRS morphology (LBBB vs non-LBBB), QRS duration (≥ 150 ms vs &lt;150 ms) and heart failure etiology (ischemic vs nonischemic). Inefficient deformation was indexed by the septal systolic stretching that occurred after shortening (SRSsept) and the absolute differences between peak strain and end-systolic strain across 16 segments (SDI). Time to peak strain was measured to derive the septal to lateral delay and the 12-segment standard deviation of time to peak strain. CRT response was defined as a 6-month end-systolic volume reduction ≥ 15%. Results: Patients with 1 of the 4 favorable characteristics were more likely to exhibit other favorable characteristics and had greater amounts of inefficient deformation than those without. In contrast, time-delay indices were not significantly different in any pairwise comparison except for that between LBBB and non-LBBB patients. Of the 38 patients for whom 6-month follow-up data was available, CRT response was found in 22 (58%). SRSsept and SDI rather than time-delay indices provided significant incremental value over clinical characteristics when predicting CRT response. Conclusions: Combined SRSsept (or SDI) and favorable characteristics may help identify CRT responders.
Mesenchymal and Osteoblastic Cells Isolated from Multiple Myeloma Patients Reveal a Different Behavior, Phenotype and Gene Expression Profiling in Relationship with the Presence of Osteolytic Bone Lesions.
Authors: Nicola Giuliani, Gina Lisignoli, Katia Todoerti, Sara Tagliaferri, Cristina Manferdini, Beatrice Tonnarelli, Luca Agnelli, Francesca Morandi, Monica Crugnola, Giorgio Lambertenghi Deliliers, Vittorio Rizzoli, Antonino Neri
Journal: Blood (2006)
P07.17 Automated grade prediction of glioma patients based on magnetic resonance imaging and a random forests approach
Authors: S. Bonte, I. Goethals, R. Van Holen
Journal: Neuro-Oncology (2016)

An automated brain tumour classification method is presented which is able to distinguish between low-grade and high-grade glioma on conventional MRI scans. Per patient, 208 quantitative features are extracted from a manually annotated brain tumour database of 274 patients. These features were then used to train a Random Forests classification algorithm. We achieved a high-grade prediction sensitivity of 85.5% and specificity of 83.3%, with a global accuracy of 85.0%.
Skin Lesions in Malignancy
Authors: Luis Paz-Ares, Esther Olivia, Robert W. Carey, Matthew R. Smith
Journal: Journal of Clinical Oncology (2001)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.7.2099 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11283145 Skin Lesions in Malignancy Case 2. Skin Metastases From Prostate Adenocarcinoma Luis Paz-AresxLuis Paz-AresSearch for articles by this author , Esther OliviaxEsther OliviaSearch for articles by this author , Robert W. CareyxRobert W. CareySearch for articles by this author , Matthew R. SmithxMatthew R. SmithSearch for articles by this author Show More Massachusetts General Hospital, Harvard Medical School, Boston, MA, Copyright © 2001 American Society of Clinical Oncology https://doi.org/10.1200/JCO.2001.19.7.2099 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
Pharmacokinetics of Ganciclovir Following Oral Valganciclovir Versus Intravenous Ganciclovir in Allogeneic Hematopoietic Stem-Cell Transplant Patients with Stable Graft-Versus-Host Disease of the Gastrointestinal Tract.
Authors: Drew J. Winston, Voravit Ratanatharathorn, Lindsey Baden, Christos Emmanouilides, Don Gabriel, Sherry Li, W. Robert Lange
Journal: Blood (2004)
Reconstitution Of The Microvascular Thrombopoietic Niche Reveals Cross-Talk Between Megakaryocytes and The Microvasculature
Authors: Sijie Sun, Shirin Feghhi, Xiaoji Chen, Jo Anna Reems, Beverly Torok-Storb, Nathan Sniadecki, Dayong Gao, José A López, Ying Zheng
Journal: Blood (2013)
Pubic apophysitis: 6 questions that need answers before I'm convinced it's a new clinical condition
Authors: Matthieu Sailly, Rod Whiteley, John Read, Amanda Johnson, Per Hölmich
Journal: British Journal of Sports Medicine (2016)

Author response

We thank our colleague Dr Garvey for his interest1 in our paper,2 and take this opportunity to address his queries on the important topic of groin pain in sport.3 

First, two independent radiologists (JR, BG) classified the asymptomatic cohort according to the classification system developed by the first author based on the apparent normal development of the pubic apophysis. A third radiologist assessed the symptomatic group's imaging and contributed to the diagnosis as part of the usual care of these injured athletes within our institution.

The diagnosis of pubic apophysitis, as with all apophysitis cases', is clinical supported by radiology. The first step in …
Autologous Hematopoietic Stem Cell Transplantation (HSCT) for Autoimmune Diseases: 10 Years Experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases
Authors: Dominique Farge, Myriam Labopin, Alan Tyndall, Athanasios Fassas, Gian Luigi Mancardi, Jaap Van Laar, Jian Ouyang, Tomas Kozak, John Moore, Ina Kötter, Virginie Chesnel, Alberto Marmont, Alois Gratwohl, Riccardo Saccardi
Journal: Blood (2008)
A Prospective, Randomized, Phase III Study of Enoxaparin Versus Aspirin Versus Low-Fixed-Dose of Warfarin in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Containing Regimens.
Authors: Antonio Palumbo, Michele Cavo, Sara Bringhen, Giulia Perrone, Valeria Magarotto, Francesca Patriarca, Maria Teresa Petrucci, Monica Galli, Francesco Di Raimondo, Davide Rossi, Roberto Marasca, Massimo Offidani, Maria Goldaniga, Paolo Corradini, Claudia Crippa, Lucio Catalano, Vincenzo Callea, Antonella Gozzini, Patrizia Tosi, Mario Boccadoro
Journal: Blood (2007)
Immunogenicity of Artificial Dendritic Cells Is Upregulated by ROCK Inhibition-Mediated Dendrite Formation.
Authors: Makito Tanaka, Tetsuro Sasada, Tetsuya Nakamoto, Sascha Ansén, Osamu Imataki, Alla Berezovskaya, Marcus Butler, Lee Nadler, Naoto Hirano
Journal: Blood (2009)
Neonatal Mouse–Derived Engineered Cardiac Tissue
Authors: W.J. de Lange, L.F. Hegge, A.C. Grimes, C.W. Tong, T.M. Brost, R.L. Moss, J.C. Ralphe
Journal: Circulation Research (2011)

Rationale: Cardiomyocytes cultured in a mechanically active 3-dimensional configuration can be used for studies that correlate contractile performance to cellular physiology. Current engineered cardiac tissue (ECT) models use cells derived from either rat or chick hearts. Development of a murine ECT would provide access to many existing models of cardiac disease and open the possibility of performing targeted genetic manipulation with the ability to directly assess contractile and molecular variables. Objective: To generate, characterize, and validate mouse ECT with a physiologically relevant model of hypertrophic cardiomyopathy. Methods and Results: We generated mechanically integrated ECT using isolated neonatal mouse cardiac cells derived from both wild-type and myosin-binding protein C (cMyBP-C)–null mouse hearts. The murine ECTs produced consistent contractile forces that followed the Frank-Starling law and accepted physiological pacing. cMyBP-C–null ECTs showed characteristic acceleration of contraction kinetics. Adenovirus-mediated expression of human cMyBP-C in murine cMyBP-C–null ECT restored contractile properties to levels indistinguishable from those of wild-type ECT. Importantly, the cardiomyocytes used to construct the cMyBP-C −/− ECT had yet to undergo the significant hypertrophic remodeling that occurs in vivo. Thus, this murine ECT model reveals a contractile phenotype that is specific to the genetic mutation rather than to secondary remodeling events. Conclusions: Data presented here show mouse ECT to be an efficient and cost-effective platform to study the primary effects of genetic manipulation on cardiac contractile function. This model provides a previously unavailable tool to study specific sarcomeric protein mutations in an intact mammalian muscle system.
Both the Activation Kinetics and the Frequency of Regulatory T Cells Determine the Ability to Generate Primary Anti-Tumor and Pathogen- Specific Immune Responses from a Naïve Donor T Cell Repertoire
Authors: Inge Jedema, Jeanette Pots, Marian van de Meent, Roel Willemze, J.H. Frederik Falkenburg
Journal: Blood (2008)
Mannan-Binding Lectin-Associated Serine Protease 2 variant is strongly associated with the development of non-anastomotic biliary strictures after OLT and Budd-Chiari syndrome
Authors: Bert-Jan de Rooij, Kerem Sebib Korkmaz, Hein W. Verspaget, Minneke J. Coenraad, Robert J. Porte, Bart van Hoek
Journal: Hepatology (2012)
Role of the IL-6 Pathway in Multiple Myeloma Cell Growth and Its Implications in Target Gene Hypermethylation.
Authors: Susan B. Ingersoll, Natalie D. Thoni, Farhana Ahmed, Kimberly A. Monahan, Lizette Caballero, Anginett Batista, Sarfraz Ahmad, John R. Edwards
Journal: Blood (2007)